This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Investigational New Drugs Open Access 01 December 2023
-
Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses
Journal of Translational Medicine Open Access 19 July 2023
-
Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
BMC Medicine Open Access 25 November 2021
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Li, X., Song, W., Shao, C., Shi, Y. & Han, W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell. Mol. Immunol. 16, 28–39 (2019).
Lantuejoul, S., Le Stang, N., Damiola, F., Scherpereel, A. & Galateau-Sallé, F. PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better? J. Thorac. Oncol. 12, 778–781 (2017).
Mimura, K. et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109, 43–53 (2018).
Kao, S. C. et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J. Thorac. Oncol. 12, 1421–1433 (2017).
Calabrò, L. et al. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol. Immunother. 64, 105–112 (2015).
Frigola, X. et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 17, 1915–1923 (2011).
Gong, B. et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J. Exp. Med. 216, 982–1000 (2019).
Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3+T cells highly expressing PD-L1 and the PD-L1+tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993–2005 (2016).
Acknowledgements
This work was supported by grants from the Italian Ministry of Health (5x1000 funds 2014 and 2015; Ricerca Corrente 2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Pistillo, M.P., Carosio, R., Banelli, B. et al. IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade. Cell Mol Immunol 17, 410–411 (2020). https://doi.org/10.1038/s41423-019-0245-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-019-0245-x
This article is cited by
-
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Investigational New Drugs (2024)
-
Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses
Journal of Translational Medicine (2023)
-
c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation
Nature Cancer (2023)
-
Porphyrin-based metal—organic framework nanocrystals for combination of immune and sonodynamic therapy
Nano Research (2023)
-
Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome
Cancer Immunology, Immunotherapy (2023)